True Wealth Design’s C4 Therapeutics CCCC Stock Holding History

True Wealth Design’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31	Closed	-$45	–	2742
2025 Q2	$45	Buy	31 +22	+244%	+$32	﹤0.01%	2401
2025 Q1	$15	Buy	+9	New	+$27	﹤0.01%	2613

Other funds holding CCCC

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

True Wealth Design's CCCC Position: Q3 2025 in Review

True Wealth Design sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 31 shares — an estimated $45 sold.

True Wealth Design first reported a position in CCCC in Q1 2025 and held it in 2 quarters. The position peaked at $45 in Q2 2025. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

True Wealth Design reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
True Wealth Design sold 31 C4 Therapeutics shares in Q3 2025, an estimated $45.
True Wealth Design first reported a position in C4 Therapeutics in Q1 2025 and held it in 2 quarters.
True Wealth Design's C4 Therapeutics position peaked at $45 in Q2 2025.
97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.